The purpose of this study was to evaluate a contribution of polymorphic cytochrome P450 (CYP) 3A5 to the oxidation of diltiazem, midazolam and testosterone by liver microsomes from Japanese subjects. Twentyseven liver samples were classied into three groups according to the CYP3A5 geno types; CYP3A5*1 W *1 (n3), *1 W *3 (n12) and *3 W *3 (n12). The results of genotyping and immunochemical quantitation of CYP3A5 protein showed a good accordance between the CYP3A5 genotype and CYP3A5 content but not CYP3A4 content in liver microsomes. The expression levels of hepatic CYP3A5 protein ranged from 20 to 60z of the sum of CYP3A4 and CYP3A5 contents in sub jects with at least one wild type allele (*1). The CYP3A5 contents correlated well with liver microsomal activities of diltiazem Ndemethylation, midazolam 1? and 4hydroxylations and testosterone 6bhydrox ylation among subjects carrying at least one * 1 allele. In addition, the correlation coecients of CYP3A5 contents with the rates of diltiazem Ndemethylation, midazolam 1?hydroxylation and testosterone 6b hydroxylation were higher than those of CYP3A4, although the value of CYP3A5 with the midazolam 4hydroxylation rate was similar to that of CYP3A4. Kinetic analyses revealed a biphasic diltiazem Ndemethylation in liver microsomes from subjects carrying the *1 allele. The apparent V max W K m values for recombinant CYP3A5 indicated the greater contributions to diltiazem Ndemethylation and midazol am 1?hydroxylation as compared with CYP3A4. These results suggest that polymorphic CYP3A5 contributes markedly to the drug oxidations, particularly diltiazem Ndemethylation, midazolam 1? hydroxylation and testosterone 6bhydroxylation by liver microsomes from Japanese subjects.
Introduction
Cytochrome P450 (CYP) comprises a superfamily of enzymes responsible for the oxidations of various en dogenous and exogenous compounds including drugs, toxicants and procarcinogens. 1) CYP3A is one of the major subfamilies of CYP expressed in human livers. 2) This subfamily has been known to be involved in the metabolism of more than 50z of clinically used drugs, such as diltiazem, midazolam and erythromycin. 3) CYP3As are also responsible for the bioactivation of procarcinogens including aatoxin B 1 . 4, 5) The human CYP3A subfamily consists of CYP3A4, 6, 7) CYP3A5, 810) CYP3A7 11) and CYP3A43. 12) CYP3A4 is the most abundant form of CYP3A (¿30z of the total CYP content) expressed in human adult livers.
2) CYP3A7 was originally isolated from human fetal livers 11) and was demonstrated as a fetalspecic form of CYP3A, 13) while a few reports have appeared on the existence of CYP3A7 in adult livers from normal Caucasian subjects 14) and Japanese patients with hepatocellular carcinoma. 15) CYP3A43 is a minor isoform of CYP3A expressed in adult livers. 12) CYP3A5 is polymorphically expressed in human adult and fetal livers. 8, 9) Recently, it was demonstrated that the poly morphic expression of CYP3A5 is mainly attributed to a single nucleotide substitution in intron 3, referred to as CYP3A5 * 3.
16) The content of CYP3A5 accounts for approximately 20z of CYP3A contents in adult livers. 9) A recent report has also shown that CYP3A5 is ex pressed at an equivalent level of CYP3A4 in some livers of Caucasians and African Americans. 16) CYP3A5 is capable of catalyzing midazolam 1? hydroxylation more eciently than CYP3A4. 17) It has also been reported that CYP3A5 expressed in liver microsomes from Caucasians and African Americans contributes to midazolam metabolism. 16) However, the contribution of CYP3A5 to the other CYP3Amediated drug oxidations has not been examined extensively.
The purpose of this study was to clarify the role of CYP3A5 in the drug oxidations in liver microsomes from Japanese subjects. We report herein that CYP3A5 contributes to the metabolism of diltiazem, midazolam and testosterone to dierent extents. In particular, CYP3A5 exhibited great contributions to the diltiazem Ndemethylation, midazolam 1?hydroxylation and testosterone 6bhydroxylation, whereas CYP3A5 and CYP3A4 contributed equally to the midazolam 4 hydroxylation.
Materials and Methods
Materials: NDesmethyldiltiazem was a gift from Tanabe Seiyaku (Osaka, Japan). Rabbit antihuman CYP3A4 antibodies were provided by Nosan Corpora tion (Tokyo, Japan). Rabbit antihuman CYP3A5 an tibodies were purchased from Gentest (Woburn, MA). Other chemicals were obtained from the following sources: midazolam, 1? and 4hydroxymidazolam and 6bhydroxytestosterone were from Daiichi Pure Chemi cals (Tokyo, Japan); diltiazem and testosterone were from Wako Pure Chemicals (Osaka, Japan); NADP { , glucose 6phosphate and glucose 6phosphate de hydrogenase were from Oriental Yeast (Tokyo, Japan). All other chemicals were of the highest grade commer cially available.
Human liver microsomes: Human livers were obtained from patients after pathological examination of specimens isolated after death or during hepatic surgery.
18) The use of the human livers for these studies was approved by the Ethics Committee of Hokkaido University. Liver samples were stored at |809 C until use. Liver microsomes were prepared and suspended in 10 mM TrisHCl buer (pH 7.4) containing 1 mM EDTA and 20z (v W v) glycerol as described previous ly.
19 ) The microsomal protein was determined by using Pierce BCA Protein Assay Kit (Pierce Chemical, Rock ford, IL) with bovine serum albumin as a standard.
Genotyping of genomic DNA from human livers: Genomic DNA was isolated from human livers accord ing to a method reported previously. 20) A genotyping method for the mutated allele (*3) of the CYP3A5 gene was performed using a realtime polymerase chain reac tion (PCR) and uorescent probe melting point analysis on the LightCycler TM (Roche Diagnostics, Somerville, NJ). Oligonucleotide primers were designed using the CYP3A5 sequence obtained from GenBank database (accession number; NTä031809.1). A 318bp fragment of the intron 3 of the CYP3A5 gene was amplied using the primers 3A5*3F (5?CTT AAC GAA TGC TCT  ACT GTC3?) and 3A5*3R (5?AGT TGA CCT TCA  TAC GTT CTG3? ). The mutation site in the CYP3A5*3 allele was covered by a mutant detection probe LC3A5 * 3FITC (5?TGT CTT TCA GTA TCT CTT C3?) which was labeled with uorescein at the 3? terminus. The adjacent anchor probe LC3A5*3Red640 (5?CTG TTT GGA CCA CAT TAC CC3?) was la beled with the LightCycler Red640 at the 5?terminus and phosphorylated at the 3?terminus. PCR reactions were carried out in a nal volume of 20 mL consisting of 50 ng of genomic DNA, 3.0 mM MgCl 2 , 0.5 mM ampli cation primers 3A5*3F and 3A5*3R, 0.2 mM LC3A5*3 FITC probe and 0.4 mM LC3A5*3Red640 anchor. As a reaction buer, the LightCycler FastStart DNA Master Hybridization Probes were used (Roche Molecular Biochemicals, Mannheim, Germany). The cycling pro gram consisted of a 10 min initial denaturation at 959 C and 50 cycles of 959 C for 5 s, 609 C for 5 s and 729 C for 12 s, with a maximum ramp rate. The analytical melting program was 959 C for 30 s and 409 C for 30 s, increasing to 659 C at a ramp rate of 0.19 C W s, with continuous uorescence acquisition.
Immunoquantitation of CYP3A5 and CYP3A4 proteins expressed in human liver microsomes: SDS PAGE was performed using an 8z acrylamide gel as described previously. 21) Microsomal protein (510 mg) was separated and transferred onto an Immobilon mem brane (Millipore, Bedford, MA). Immunoblot quantita tion was performed using rabbit antibodies to human CYP3A5 and CYP3A4 as primary antibodies and horseradish peroxidaseconjugated antirabbit im munoglobulin (Gentest) as a secondary antibody. CYP3A5 and CYP3A4 proteins were visualized by staining with 3?diaminobenzidine. Expression levels of these proteins were quantied from calibration curves obtained with microsomal protein from baculovirus infected insect cells expressing recombinant human CYP3A5 and CYP3A4 (Gentest), respectively.
Preparation of membrane fraction from genetically engineered E. coli cells expressing CYP3A5 or CYP3A4 and NADPHcytochrome P450 reductase: The 5? terminus of CYP3A5 cDNA was modied as described previously. 22) A bicistronic plasmid carrying CYP3A5 and the NADPHcytochrome P450 reductase (reduc tase) cDNAs was constructed according to the method reported by Iwata et al. 23) E. coli DH5a strain harboring CYP3A4 together with the reductase was established by Iwata et al. 23) CYP3A5 or CYP3A4 and the reductase in the genetically engineered E. coli cells were expressed as reported previously. 23) Membranes were prepared from E. coli cells harboring each isoform of CYP3A and the reductase as described previously.
24) The fraction was suspended in 100 mM TrisHCl buer (pH 7.5) contain ing 20z (v W v) glycerol and stored at |809 C until use. The content of CYP in the membrane fraction was determined according to the method reported previous ly.
25 ) The reductase activity was measured as described previously. 26) One unit of the reductase was dened as the amount of the enzyme that reduced 1 mmol of cytochrome c W min. Human cytochrome b 5 (b 5 ) in the genetically engineered E. coli cells was expressed follow ing a method of Holmans et al. 27) and puried as report ed previously.
28)
Enzyme assays: Unless otherwise stated, a typical incubation mixture consisted of 100 mM sodium potas sium phosphate buer (pH 7.4), 50 mM EDTA, a sub strate and human liver microsomes (75 mg protein) in a nal volume of 200 mL. After preincubation at 379 C for 5 min, reactions were initiated by the addition of an NADPHgenerating system (0.5 mM NADP { , 5 mM glucose 6phosphate and 1 unit W mL glucose 6 phosphate dehydrogenase). All determinations were performed in duplicate.
Diltiazem Ndemethylase activity was determined as described below. An incubation mixture consisted of 5 to 500 mM diltiazem. Incubations were carried out at 379 C for 10 min and terminated by adding 10 mL of 70z (w W v) perchloric acid. After removal of protein by centrifugation, 150 mL of the supernatant was subjected to highperformance liquid chromatography equipped with a Mightysil RP18 GP column (4.6~150 mm, 5 mm, Kanto Chemical, Tokyo, Japan). Fifty mM potassium phosphate buer (pH 6.0) containing 30z (v W v) acetonitrile was used as a mobile phase. Elution was performed at a ow rate of 1.5 mL W min. The formation of Ndesmethyldiltiazem was monitored at a wavelength of 238 nm.
Midazolam 1? and 4hydroxylase activities were determined as described previously, 29) except that an incubation mixture contained 100 mM potassium phos phate buer (pH 7.4) and 10 mM midazolam. Incuba tions were carried out at 379 C for 10 min and terminat ed by adding 200 mL of cold methanol. After removal of protein by centrifugation, 200 mL of the supernatant was subjected to highperformance liquid chro matography equipped with a Mightysil RP18 GP column (4.6~150 mm, 5 mm, Kanto Chemical).
Testosterone 6bhydroxylase activity was determined according to the method reported previously, 30) except that the typical incubation mixture contained 50 mM testosterone in a nal volume of 250 mL.
Kinetic analyses of oxidations catalyzed by CYP3A expressed in E. coli membranes: Membranes from E. coli cells coexpressing CYP3A5 or CYP3A4 and the reductase, and a puried recombinant human b 5 prepa ration were employed as the enzyme source. Incubations were performed as described in the enzyme assays, except that incubation mixtures consisted of 10 pmol of CYP3A and 20 pmol of b5 (for the Ndemethylation of diltiazem) or 5 pmol of CYP3A and 10 pmol of b 5 (for the 1? and 4hydroxylations of midazolam and 6b hydroxylation of testosterone). To determine kinetic parameters, substrate concentrations ranged from 0.78 to 400 mM (diltiazem), from 0.78 to 100 mM (mid azolam) and from 12.5 to 500 mM (testosterone). Data points were tted to the MichaelisMenten equation by nonlinear leastsquares regression analysis with Origin 6.1J software (OriginLab, Northampton, MA).
Statistical analyses: Univariate or multivariate linear regression analysis was performed to compare oxidation rates with contents of CYP3A4 and W or CYP3A5 using a program InStat (GraphPad Software, San Diego, CA). Analysis of variance was used to deter mine whether the model was statistically signicant with pº0.05.
Results
Genotyping of the CYP3A5 gene: We developed a rapid and a reproducible genotyping method for the wild type allele (*1) and mutated allele (*3) using a real time PCR. Melting curves after PCR reactions for the CYP3A5 * 1 W * 1, * 1 W * 3 and * 3 W * 3 genotypes are shown in Fig. 1 . Individuals with the CYP3A5*1 W *1 genotype had the lowest melting temperature (Tm) at 489 C. Individuals with the CYP3A5*1 W *3 genotype had two Tms at 489 C and 559 C. Individuals with the CYP3A5*3 W * 3 genotype had the highest Tm at 559 C. Accordingly, liver samples from 27 Japanese subjects were genotyped for the CYP3A5 * 1 W * 1 (n3), * 1 W * 3 (n12) and * 3 W * 3 (n12). Association of CYP3A5 and CYP3A4 contents with the CYP3A5 genotypes: The expression levels of CYP3A5 and CYP3A4 proteins were determined im munochemically with liver microsomes from the 27 Japanese subjects (Fig. 2) . Liver microsomes from subjects with the CYP3A5*1 W *1 or *1 W *3 genotypes expressed CYP3A5 protein ranging from 15 to 55 pmol W mg protein, accounting for 20 to 60z of the sum of CYP3A4 and CYP3A5 contents ( Fig. 2A) . On the other hand, the expression level of CYP3A5 in liver micro somes of subjects homozygous for the mutated allele ( * 3) was less than 5 pmol W mg protein ( Fig. 2A) . CYP3A4 was expressed in all liver samples examined; the content varied from 17 to 127 pmol W mg protein (Fig. 2B) . There was no dierence in the mean expres sion level of CYP3A4 between subjects possessing the CYP3A5 * 1 W * 1 or * 1 W * 3 genotypes and the CYP3A5 * 3 W *3 genotype (46}26 and 49}25 pmol W mg protein, mean}S.D., respectively), indicating that the mutated allele (*3) of the CYP3A5 gene does not aect the ex pression level of CYP3A4. Total CYP3A content in liver microsomes from subjects with at least one wild type allele (*1) (78}31 pmol W mg protein, n15) was signicantly higher than that from subjects with the CYP3A5 * 3 W * 3 genotype (53}26 pmol W mg protein, n 12, p0.03).
Correlation between catalytic activities and CYP3A contents in individual liver microsomes from Japanese subjects: To clarify the involvement of CYP3A5 in the diltiazem Ndemethylation, we examined a correlation between the activities and CYP3A5 or CYP3A4 con tents in individual liver microsomes from subjects with dierent CYP3A5 genotypes (Fig. 3) . The sum of Fig. 3 . Correlation between diltiazem Ndemethylase activities and CYP3A contents in individual liver microsomes of subjects with the CYP3A5*1 W *1 or *1 W *3 (AC) and CYP3A5*3 W *3 (DF) genotypes. Rates of the diltiazem Ndemethylation at a substrate concentration of 20 mM were determined with liver microsomes from subjects carrying the CYP3A5*1 W *1 (ä), *1 W *3 (#) and *3 W *3 (å) genotypes as described in the text. The univariate linear regression analysis was performed to compare the Ndemethylase activities with the contents of CYP3A5, CYP3A4 and sum of these CYP3A proteins. Respective correlation coecients represent statistically signicant linear regression of the Ndemethylase activities and CYP3A contents with pº0.05. The CYP3A5 and CYP3A4 contents made a signicant contribution with pº0.01 and pº0.05, respectively. f The amounts of CYP3A5 but not CYP3A4 made a signicant contribution with pº0.05 and p0.09, respectively. The amounts of CYP3A5 but not CYP3A4 made a signicant contribution with pº0.05 and p0.07, respectively. h The CYP3A5 and CYP3A4 contents made a signicant contribution with pº0.05. The amounts of CYP3A4 but not CYP3A5 made signicant contributions with pº0.01 and pÀ0.24, respectively.
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CYP3A4 and CYP3A5 contents in liver samples of sub jects carrying at least one wild type allele (*1) correlated well with the Ndemethylase activities (Fig. 3C) . Fur thermore, the CYP3A5 contents showed a fairly good correlation with the activities in contrast to CYP3A4 contents (Figs. 3A and 3B), suggesting that CYP3A5 is responsible for the Ndemethylation. On the other hand, the CYP3A4 contents and sum of CYP3A4 and CYP3A5 contents correlated highly with the activities of liver microsomes from subjects homozygous for the mutated allele ( * 3) (Figs. 3E and 3F) . Correlation coecients between CYP3A5 and W or CYP3A4 contents and the drug oxidation rates in individual liver microsomes are summarized in Table 1 . Good correlations of CYP3A5 contents with all the oxidations examined were seen in liver microsomes from subjects carrying the CYP3A5*1 W *1 or *1 W *3 geno types. In contrast, the CYP3A4 contents correlated only with the diltiazem Ndemethylation at a substrate con centration of 200 mM and midazolam 4hydroxylation. Multivariate regression analyses showed that the amounts of CYP3A4 plus CYP3A5 correlated sig nicantly with all the oxidation rates studied in liver microsomes from subjects with at least one wild type allele (*1) (0.47ÃR 2 Ã0.65, pº0.05). There were sig nicant contributions of the CYP3A5 contents to all the oxidations examined (pº0.05), although CYP3A4 contents signicantly contributed only to the diltiazem Ndemethylation at a substrate concentration of 200 mM and midazolam 4hydroxylation (pº0.05). The correla tion coecients of CYP3A5 contents with the rates of diltiazem Ndemethylation, midazolam 1?hydroxyl ation and testosterone 6bhydroxylation were greater as compared with those of CYP3A4, suggesting that CYP3A5 may contribute markedly to these oxidations. In the midazolam 4hydroxylation, the coecient with CYP3A5 contents was similar to that with CYP3A4 contents. In liver microsomes from the subjects with the CYP3A5*3 W *3 genotype, on the other hand, the CYP3A4 contents and CYP3A4 plus CYP3A5 contents correlated highly with all the drug oxidation rates inves tigated (pº0.01). Correlation coecients of CYP3A4 contents with the activities were comparable to those of CYP3A4 plus CYP3A5 contents, indicating that CYP3A4 may contribute largely to the oxidations in liver microsomes with little or no expression of CYP3A5. Lower correlation coecients between CYP3A4 contents and the drug oxidation rates were seen in liver samples of subjects carrying at least one wild type allele (*1) in comparison to those of subjects with the CYP3A5 * 3 W * 3 genotype, being considered that the polymorphic expression of CYP3A5 led to relatively minor contributions of CYP3A4 to the oxidations.
Role of CYP3A5 in diltiazem Ndemethylation: EadieHofstee plots for the diltiazem Ndemethylation by liver microsomes from subjects homozygous for the wild type allele ( * 1) or mutated allele ( * 3) are shown in Fig. 4 . A biphasic pattern in the Ndemethylation was seen in the liver microsomes from a subject carrying the CYP3A5*1 W *1 genotype, although those from a subject with the CYP3A5*3 W *3 genotype showed a monophasic pattern, suggesting that not only CYP3A4 but also CYP3A5 are involved in the oxidation by liver micro somes from the subject with the CYP3A5 * 1 allele.
Examination for the relative contributions of CYP3A5 and CYP3A4 to drug oxidations using the membrane fraction of genetically engineered E. coli: To support an assumption on the relative contributions of CYP3A5 and CYP3A4 to the metabolism of diltia zem, midazolam and testosterone, kinetic parameters for the oxidations were determined by using CYP3A5 and CYP3A4 expressed in E. coli membranes ( Table 2) . In diltiazem Ndemethylation and midazolam 1?hydro xylation, the apparent V max W K m values for CYP3A5 were 2.5 and 2.4 times higher than those for CYP3A4, respectively, supporting the surmise that CYP3A5 con tributes markedly to these oxidations in liver micro somes from subjects with at least one wild type allele ( * 1). On the other hand, the values for the testosterone 6bhydroxylation and midazolam 4hydroxylation by CYP3A5 were 0.41 and 0.18 of those for CYP3A4, respectively.
Discussion
Polymorphism of the CYP3A5 gene can be mainly explained by the CYP3A5*3 and *6 alleles, which cause alternative splicing and protein truncation. 16) However, a recent report has shown that 200 healthy Japanese subjects carry the CYP3A5*1 and W or *3 alleles but not CYP3A5*6 allele.
31) Thus, we developed a rapid genotyping method allowing us to distinguish the wild type ( * 1) and mutated ( * 3) alleles using a realtime PCR. The allelic frequency of the wild type allele (*1) in Japanese was 33z. This value is similar to that reported previously by Hustert et al., 32) but is greater than that reported by Fukuen et al.
31) The frequencies of the CYP3A5 * 1 W * 1 and * 1 W * 3 genotypes in this study were estimated as 11.1 and 44.4z, respectively, which were higher than those reported by Fukuen et al.
31)
A good relationship between the CYP3A5 genotype and expression level of CYP3A5 protein was seen in Japanese livers in the present study. CYP3A4 contents did not correlate with any of the CYP3A5 genotypes and CYP3A5 contents, suggesting that the expression of CYP3A5 and CYP3A4 is regulated independently. This was in contrast to results that expression levels of CYP3A5 and CYP3A4 were highly correlated in the Caucasian livers with the CYP3A5*1 W *3 genotype. 33) Thus, we propose that the polymorphism of the CYP3A5 gene does not appear to aect the expression of CYP3A4.
The expression levels of hepatic CYP3A5 protein among subjects carrying the CYP3A5*1 W *1 or *1 W *3 genotypes indicate that CYP3A5 contents are higher and more variable than that reported previously.
15) It was shown that the content of CYP3A5 accounted for approximately 20z of the total CYP3A content in the liver expressing this protein. 9) However, it has been also reported that CYP3A5 represents at least 50z of the total CYP3A content in adult livers including onethird of Caucasians and more than onehalf of African Americans. 16) Taken together with our results and their ndings, CYP3A5 is likely to contribute markedly to the total CYP3A content not only in Caucasians and Afri can Americans but also Japanese with at least one wild type allele (*1).
It was demonstrated that CYP3As were major en zymes catalyzing the Ndemethylation of diltiazem. 34) In the present study, liver microsomal activities of the 36) has shown that the ratio for recombinant CYP3A5 is higher than that for CYP3A4 at substrate concentrations up to 100 mM. In our current study, the average ratio for the liver microsomes from subjects carrying at least one wild type allele (*1) were higher than that for subjects with the CYP3A5*3 W *3 genotype (data not shown). This is compatible with those report ed previously, 16, 17) indicating that the polymorphic expression of CYP3A5 aects the metabolite ratio for the midazolam hydroxylations.
A previous report showed that CYP3A5 contents correlated well with the rates of nifedipine oxidation as estimated from the contents of each CYP3A isoform and the oxidation rates in human liver microsomes. 15) More recently, it has been reported that CYP3A5 content accounts for 32z of the variability in total midazolam hydroxylation rates (sum of formation rates of 1? and 4hydroxymidazolam). 33) In this study, good correlations between CYP3A5 contents and the activi ties of diltiazem Ndemethylation, midazolam 1? and 4 hydroxylations and testosterone 6bhydroxylation were seen in liver microsomes from subjects with the CYP3A5 * 1 W * 1 or * 1 W * 3 genotypes. In contrast to our observation, WestlindJohnsson et al. 37) failed to demonstrate that CYP3A5 contributed to the testoster one 6bhydroxylation in liver microsomes from Cauca sians. The reason for this discrepancy may be caused by a small number of liver samples expressing CYP3A5 (only n5). The apparent V max W K m values for recom binant CYP3A5 indicated the lower contributions of this enzyme to the testosterone 6bhydroxylation and midazolam 4hydroxylation. These results suggest that both relative activities and amounts of CYP3A5 and CYP3A4 may determine the contribution of these CYP3A isoforms to the drug oxidations in human liver microsomes.
The question of whether CYP3A5 plays a role in the metabolism of CYP3A substrates in vivo is raised from our results and previous ndings. 16, 17) However, the eects of the CYP3A5 genotypes on the disposition of CYP3A substrates have not been investigated exten sively. A more recent study has shown that the disposi tion of midazolam in vivo was not aected by the CYP3A5 genotypes. 38) The reason for this is yet unclear, but the role of CYP3A5 in the CYP3Amediated drug metabolism needs to be examined as Shih and Huang 38) have pointed out. One approach is to compare the ratio of formation rates of two metabolites, such as mid azolam and alprazolam, for the various CYP3A5 geno types, since CYP3A5 and CYP3A4 exhibit dierent ratios depending on the substrates used. 17, 36) CYP3A5 is a major form of CYP3A expressed in various extrahepatic tissues such as adult kidney, 39) peripheral blood, 40) normal lung and lung tumors. 41) It has been reported that CYP3A5 and CYP3A4 eciently catalyze the 4hydroxylation of cyclophosphamide and ifosfamide to produce therapeutically active metabo lites. 42) These ndings suggest the importance of CYP3A5 on the drug metabolism in these extrahepatic tissues.
In conclusion, this is the rst study to demonstrate that CYP3A5 contributes to the CYP3Amediated drug oxidations by human liver microsomes. CYP3A5 indi cated a large degree of contributions to the diltiazem Ndemethylation, midazolam 1?hydroxylation and testosterone 6bhydroxylation, although CYP3A5 and CYP3A4 contributed equally to the midazolam 4 hydroxylation. The present results strongly suggest that polymorphic expression of CYP3A5 may partly account for the variation in the metabolism of CYP3A sub strates.
